Diskussion zur BICO Group Aktie WKN: A2PX00 ISIN: SE0013647385 Forum: Aktien User: Hedgehog3

Ich überlege ob ich mit dem nachkaufen beginnen soll. Habt ihr bereits eure Position weiter aufgebaut ? Ist es bereits die Bodenbildung ?

Guckt mal bei Prof.goldgraf auf Instagram. Der hat genau das Thema heute in einem Post dargestellt. Generell eine sehr gute Adresse für die Börse der Account.

Für das Unternehmen sollte der negative Währungseffekt keine Auswirkungen haben. Bicos Umsätze sind quer über die Welt verteilt und gut diversifiziert. Für den investierten deutschen Anleger hingegen hat der Währungseffekt schon einen direkten Effekt, da die Aktien im Original ja in Schwedischen Kronen gehandelt werden.

Wir sind auf Monatsbasis immer noch im minus.. zu krass

Wieder im Plus 👍🏻jetzt gehts los

Bico 🤤🥰

Bald sehen wir die 20 wieder 🚀😍

SCIENION Announces Study Results for PoC-BoSens, an Optofluidic-based Infectious Disease Diagnostic Platform The study demonstrated the success of an optofluidic-based Point-of-Care (PoC) diagnostic system for the analysis of protein-protein interactions. Today SCIENION, a BICO company and leading developer of miniaturized multiplex diagnostic tests, announced the completion of the diagnostic research project PoC-BoSens led by the Fraunhofer Institute for Reliability and Microintegration (IZM). The PoC-BoSens platform is a revolutionary label-free Point-of-Care device based on three-dimensional photonic bottle resonators (3D-BMRs) for real-time high-sensitive measurement of disease-relevant biomolecules. The platform leveraged the use of an automated read-out device to analyze the results of up to 4 cytokine reactions in an optofluidic cartridge. The COVID-19 pandemic has exposed the vital need for fast, affordable, and scalable infectious disease diagnostics. In the case of both novel diseases and ones that we’ve been battling for decades, a lack of effective monitoring leads to millions of preventable deaths each year. Photonic sensing platforms are revolutionizing point-of-care diagnostic methods by enabling high sensitivity, high compactness, and multiplexing capabilities for the fast and reliable detection of infectious and autoimmune diseases. The project began in 2018 and was funded by the German Federal Ministry of Education and Research. The study brought together several academic and industry partners across photonics, microfluidics, electronics, biochemistry and assay development. SCIENION was selected to participate based on its expertise in the development of miniaturized multiplex assays. The 3D-BMRs were coated with the capture probes using SCIENION’s proprietary surface functionalization and sciFLEXARRAYER dispensing technology, and then integrated into an optofluidic biochip cartridge in the medical device. The study successfully demonstrated the integration of the technological components into a tabletop system. The readout unit comprises of fully automatic control systems for fluidics and measurement process followed by automatic data analysis. The optofluidic biochip was evaluated in a two-step approach. The specific biorecognition of cytokine IL-2 utilizing 3D-BMRs in the microfluidic cartridge was stable and consistently achieved a limit of detection below 1 ng/mL. The assembled optical sensor reached Q factors between 104 and 105, leading to a sensitivity in the ng/mL level.

Aber die Aktien werden im Original ja in schwedischen Kronen gehandelt, fällt der Kurs der Kronen, fallen ja auch automatisch die Aktienkurse oder?

Aber hat das wirklich so einen negativen Effekt? Die Umsätze werden größtenteils im Ausland gemacht, demnach auch nicht in SEK bezahlt. Einzig die monetären Rücklagen werden davon getroffen, aber die sollten sowieso nicht so hoch sein.

Der negative Währungseffekt ist auch nicht ohne... in den letzten 5 Monaten sind rund 10% am Kursverfall der Schwedischen Krone drauf gegangen

Ging mir ja schon ab minus 7 prozent.😵‍💫

Das Unternehmen gibt euch halt jeden Tag die Chance günstig einzusteigen 😅😂

Und täglich grüsst das abverkaufende murmeltier

CELLINK Launches the BIO CELLX, a First of its Kind Biodispensing Platform to Automate 3D Cell Culture The BIO CELLX provides cell biologist with pre-validated protocols to eliminate barriers for automating 3D cell-based assays targeting cancer research and drug discovery. Today CELLINK, A BICO Company, launched the BIO CELLX a novel system that automates 3D cell culture workflows by leveraging pre validated protocols. The BIO CELLX builds upon CELLINK’s impressive bioprinting portfolio utilizing proven technologies like the patented Clean Chamber combined with a unique new method for effortless mixing of hydrogels and cells, high precision dispensing and automatic nozzle priming to create a system for reproducible and high throughput model generation. By introducing the concept of pre-validated protocols, the BIO CELLX provides cell biologists a solution for the development of 3D models without need for coding, CAD modelling or parameter selection and optimization. The BIO CELLX continues to harness the power of bioconvergence through the use of ECM based hydrogels provided by Advanced BioMatrix, another BICO group company. “This product is an important step in proliferating 3D cell culture and the numerous advantages it can bring to cell biologists. With the BIO CELLX we have developed a solution that effectively empowers researchers to transition to 3D cell culture workflows, providing effective and reproducible models that can truly improve research outcomes,” says Johan Norrman, CTO, CELLINK. “We are thrilled to be bringing the BIO CELLX to the drug discovery market. For the last 5 years we have developed cutting edge bioprinters and have utilized this expertise to develop an automated biodispensing platform solution that makes the power of 3D accessible to all with easy to understand set up and effortless material and cell mixing. We look forward to enabling the pharma industry with technology which we hope will bring meaningful breakthroughs in cancer research and therapy development by providing biomimetic models,” added Cecilia Edebo, CEO, CELLINK. The BIO CELLX was selected as a finalist for the New Product Award at the recent SLAS conference in Boston for its potential impact in the market.

😂👍🏻